A Phase 1 Trial of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Update From the First-in-Human Study

Russell Pachynski, MD¹; Nicholas Iannotti, MD, PhD⁴; Kim N. Chi, MD, PhD⁴ Karen Villaluna¹⁰; Brett Younginger, PhD¹⁰; Alessandra Cesano, MD, PhD¹⁰ ¹Washington University School of Medicine in St. Louis; ²Hematology Oncology Associates of the Treasure Coast; ³Memorial Sloan Kettering Cancer Centers of the Treasure Coast; ³Memorial Sloan Kettering Cancer Centers of the Treasure Coast; ⁴Winship Cancer Centers of the Treasure Centers of the Treasure Centers; ⁴Winship Cancer Centers of the Treasure Centers; ⁴Winship Nevada, [®]Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia; [®]Michael Smith Genome Sciences Centre, BC Cancer; [®]ESSA Pharma Inc.

Abstract


Background

eneration aniten, a novel class of compounds designed to inhibit androgen receptor (AR) activity by binding to the N-terminal domain (NTD). Preclinical data supports disruption of AR regulated gene transcription even in the presence of resistance mechanisms including ligand-binding (LBD) domain point mutations and truncated splice variants. Here we report preliminary results from the ongoing Phase 1 first-in-human trial of EPI-7386 in mCRPC (NCT04421222).

This Phase 1, open-label, multicenter, dose escalation (Part 1a) and expansion (Part 1b) trial was designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EPI-7386 in mCRPC patients (pts) progressing on standard of care treatment, including next genogen(s) and chemotherapy. Although originally designed to assess up to 5 doses of EPI-7386 (200, 400, 600, 800, and 1000 mg QD), two additional cohorts were added in the Phase 1a to evaluate 400 and 600 mg BID due to 600 mg QD showing exposure saturation while demonstrating a favorable safety profile. The Phase 1b is ongoing and currently evaluating the 600 mg BID dose regi-

31 pts were enrolled in the QD cohorts and 14 in the BID cohorts (8 in Phase 1a and 6 in Phase 1b). Pts enrolled in the QD schedule had a median of 4 lines of prior therapy for mCRPC, 77% received abiraterone and at least one other next generation AR inhibitor (NGAI) and 58% had at least one line of prior chemotherapy. Pts enrolled in the BID cohorts had a median of 2 prior lines of therapy for mCRPC, 75% received prior abiraterone and one NGAI, and 50% had one line of prior chemotherapy. The median number of prior treatments (including at least one NGAI) for mCRPC pts enrolled to date in the Phase 1b is 2 (no prior chemotherapy allowed for this cohort). No DLTs were observed in the dose escalation part of the study; EPI-7386 was safe and well tolerated at all doses/schedules evaluated. All related adverse events (AEs) were Grade 1 and 2 and consistent with AEs associated with NGAI. For doses above 400 mg QD, exposures were at or above those associated with antitumor activity in animal models. Evidence of antitumor activity (including duration of treatment > 12 weeks, decrease in PSA levels or increases in PSA doubling time and/or decreases in ctDNA, and/or radiographically documented tumor shrinkage) were observed in pts with fewer than 3 lines of treatment for mCRPC, no visceral metastases and no prior chemotherapy. **Conclusions**


EPI-7386 single agent was safe, well tolerated up to a daily dose of 1200 mg (600 mg BID), achieved target clinical exposures and showed preliminary signals of antitumor activity in heavily-pretreated mCRPC pts. Part 1b is open with enrollment focused on pre-chemotherapy, post-NGAI treated mCRPC pts. Two doses will be evaluated (600 mg BID and 600 mg QD) based on FDA Project Optimus recom-




Mechanism of Action of EPI-7386

The AR is activated by androgen binding to the LBD which induces the dimerization and nuclear translocation of the AR. Current AR-targeted therapies work directly or indirectly through the LBD of the AR either by competing with androgen binding to the LBD (lutamide) or by inhibiting androgen production. EPI-7386 targets the NTD and is active against wild type and altered AR forms, and therefore, can bypass many resistance mechanisms to current AR-targeted therapies.

EPI-7386 Phase 1a/1b Monotherapy Study (First-in-Human) is Designed to Answer 4 Main Questions



- therapy



- Visceral metastases permitted
- Prior chemotherapy permitted

Parameter	QD n = 31
Median age (range), yrs	72 (50-85)
<u>ECOG performance status, n (%)</u> 0 1	7 (22.6%) 24 (77.4%)
Median no. lines of prior therapy (range)	7 (4-13)
Median no. lines of prior therapy for mCRPC (range)	4 (2-10)
<u>Type of prior therapy, n (%)</u> Abiraterone ("ABI") Enzalutamide ("ENZ") Both (ABI + ENZ) Darolutamide/Apalutamide Chemotherapy	27 (87.1%) 25 (80.6%) 22 (71.0%) 4 (12.9%) 18 (58.1%)

 Patients enrolled in the Phase 1a under the **QD** dosing regimen were heavily pretreated Existing AR-directed therapies expected to be ineffective

Patients Enrolled in the Phase 1 had Rapidly Progressive Disease

Patients enrolled under the BID dosing reasons


men are by design less heavily pretreated

Yet 50% received prior chemotherapy

Phase 1a: QD Dosing Regimen				
Parameter	QD n = 31			
Median baseline PSA, (range), ng/ml	82.9 (9.70 - 284			
Median baseline PSA doubling time (range), months	2.5 (<0.0 – 35.8			
Median baseline ctDNA** % (range)	29 (4-73)			
Visceral Disease, n (%)	9 (29%)			
NSE* > 10 ng/ml, n (%)	8 (25.8%)			

All patients have rapid progressive disease as documented by rapid PSA doubling time

Patients Enrolled In Phase 1a are Enriched in Molecular Alterations Associated with Multi-drug Resistant Disease and Poor Prognosis




AR-targeted therapies

Phase 1 Design and Patient Baseline Characteristics

• First-in-human phase 1 multi-center open-label study enrolling mCRPC patients failing standard-of-care

• Two-part study: Phase 1a dose escalation followed by Phase 1b dose expansion



- Limited to \leq 3 prior lines of therapy • Exclusion of visceral metastases
- One line of prior chemotherapy permitted

Parameter	BID n = 8
Median age (range), yrs	70 (53-78)
ECOG performance status, n (%) 0 1	5 (62.5%) 3 (37.5%)
Median no. lines of prior therapy for mCPRC (range)	2 (1-4)
<u>Type of prior therapy, n (%)</u> ABI ENZ Both (ABI + ENZ) Darolutamide/Apalutamide Chemotherapy	6 (75.0%) 2 (25.0%) 2 (25.0%) 2 (25.0%) 4 (50.0%)

Median age (range), yrs	74 (62-81)
<u>ECOG performance status, n (%)</u> 0 1	4 (66.7%) 2 (33.3%)
Median no. lines of prior therapy for mCPRC (range)	2 (2)
<u>Type of prior therapy, n (%)</u> ABI ENZ Both (ABI + ENZ) Darolutamide/Apalutamide	2 (33.3%) 1 (16.6%) 3 (50.0%) 1 (16.6%)

Phase 1b - Cohort A: BID Dosing Regimen (currently ongoing)

600 mg Bl (1200 mg/da

• Limited to \leq 3 prior lines of therapy

• Exclusion of visceral metastases

• Exclusion of prior chemotherapy

Revised Protocol

BID dosing

N = 6 (expecting a total of 12)

• Patients enrolled under the BID dosing regimen are by design less heavily pretreated

Phase 1a: BID Dosing Re	Phase 1b: BID Dosing Regimen	
rameter	BID n = 8	Parameter
ian Baseline PSA levels, (range), ng/ml	10.7 (4.91- 570)	Median Baseline PSA levels, (range), ng/m
edian baseline PSA doubling time ange), months	2.8 (0.9-6.4)	Median baseline PSA doubling time*** (range), months
edian baseline ctDNA % (range)	7.5 (0-65)	NSE* > 10 ng/ml, n (%)
E* > 10 ng/ml, n (%)	1 (12.5%)	

**Percentage is based on n=5 as 2 subjects did not have NSE data available ** Doubling-time formula derived from the MSK Doubling Time Nomogram (https://www.mskcc.org/nomograms/prostate/psa_doubling_time).


		Molecular characterization	QD n = 29
		 AR-associated alterations AR amplification AR mutations AR structural alterations 	83% 48% 31% 34%
	StructuralVariant Yes No CopyNumber Gain Deletion	 Non-AR-associated alterations PI3K pathway DNA repair WNT pathway TP53 Rb1 	90% 55% 59% 21% 45% 38%
	Deep deletion Mutations	Molecular characterization	BID n = 8
	Missense Frameshift Stopgain Non-Frameshift Splice site	 AR-associated alterations AR amplification AR mutations AR structural alterations 	75% 63% 25% 13%
		 Non-AR-associated alterations PI3K pathway DNA repair WNT pathway TP53 Rb1 	63% 25% 38% 25% 25% 25%
BID Patients			

High % of alterations outside of the AR-axis are characteristic of advanced mCRPC patients unlikely to respond to


EPI-7386 is Well Tolerated at all Dose Levels and Schedules (QD and BID Regimens) Administered in the Phase 1a and 1b Cohort A (n = 45)

TRAE* Term (n=45)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Total n (%)
Anemia	4 (8.8%)	1 (2.2%)	1 (2.2%)	6 (13.3%)
Aspartate aminotransferase increased	2 (4.4%)	0 (0%)	0 (0%)	2 (4.4%)
Diarrhea	4 (8.8%)	2 (4.4%)	0 (0%)	6 (13.3%)
Fatigue	4 (8.8%)	5 (11.1%)	0 (0%)	9 (20.0%)
Hot flush	0 (0%)	4 (8.8%)	0 (0%)	4 (8.8%)
Nausea	7 (15.5%)	2 (4.4%)	0 (0%)	9 (20.0%)

- ment). Both of these events were later considered unlikely related to EPI-7386 administration.
- No apparent dose-dependency was observed
- All Grade 2 TRAEs of diarrhea occurred at doses \geq 600 mg QD



Longer Duration of Treatment is Associated with Less Prior Therapy for mCRPC



• All TRAEs are Grade 1 and 2 except one case of Grade 3 hypertension (in a patient with pre-existing Grade 2 hypertension and poor compliance to anti-hypertensive therapy) and one Grade 3 anemia (in a patient with pre-existing Grade 2 anemia and rapid bone disease progression with marrow involve-


• Dose reduction rate (6.7%) due to related AEs (2 cases of Grade 1 diarrhea, 1 case of Grade 2 diarrhea in 3 subjects)


18 SAEs Have Been Reported and All Attributed to Disease Progression or Underlying Co-morbidities

EPI-7386 Human Exposures Reached the Predicted Efficacious Thresholds Observed in Preclinical Models

- EPI-7386 has a long half-life (>24hrs) and its steady state exposure increases with higher doses
- All doses tested reached exposures above the minimum target drug threshold
- Doses > 400 mg per day of EPI-7386 exhibit AUC concentrations generally above the highest target drug threshold
- At 600 mg BID, improvement in PK parameters were noted with stable exposure >> 300K AUC throughout the first cycle, and ~ 18K ng/mL (> 30 uM) EPI-7386 as Cmin 600 mg BID was chosen as one of the doses/regimens to be further assessed in the Phase 1b
- Serum Triglyceride and LDL levels increase with higher trough level of EPI-7386.
- This effect is not observed in patients treated with statins
- Such metabolic effects have been observed with androgen deprivation therapy¹ and suggest inhibition of AR pathway and target engagement of EPI-7386

¹Choi et al. Metabolic effects of androgen deprivation therapy. Korean J Urol. 2015







Phase 1a QD Patients

- ~30% of patients across all dose levels remained on therapy longer than 3 months
- Patients who progressed before or at 12 weeks had: >10 ng/mL NSE, visceral metastases and received prior chemotherapy and >3 lines of therapy for mCRPC
- One patient was treated for 18 months and one patien
- is currently on study at 1000 mg dose QD in cycle 17 No obvious dose response observed
- Phase 1a BID Patients
- ~60% of patients across the two dose levels remained on therapy longer than 3 months
- Four of these patients received prior chemotherapy 1 patient still on study (did not receive prior chemother)


Phase 1b BID Patients

Six patients enrolled to date and 4 currently on study No patients received prior chemotherapy or had visceral disease





Heterogeneity in Tumor Response was Characteristically Observed Using AIQ's Platform




Using AIQ's technology (aiq-solutions.com), which quantifies the spatiotemporal heterogene ity of treatment response across all lesions, significant heterogeneity in tumor response to EPI-7386 was observed. Lesion categories were determined by the % change in tumor volume from the latest scan to the baseline scan.



PSA Decreases/Stabilizations were Observed in a Clinically-Defined Subset of Patients

Deeper and more durable PSA level decrease/stabiliza tion together with **increases** in PSA doubling time were observed in less pre-treated patients with no visceral disease and less DNA genom aberrations in non-AR onco genic pathways




Of 25 patients that completed three cycles of treatment but did not have a PSA decrease, 10 nevertheless showed increases in PSA doubling time¹(40% Percent change calculated from three historical measurements and the first three months on treatment. ¹Doubling-time formula derived from the MSK Doubling Time Nomogram (https://www.mskcc.org/nomogram prostate/psa_doubling_time).

Changes in Measurable Target Lesions were Observed in Patients on Therapy for More than 12 Weeks




Patients with a High Mutational Burden Across

Multiple Oncogenic Pathways Show Less Response to AR Inhibition by EPI-7386



population, the number of genomic alterations found by ctDNA correlates with the duration of EPI-738 treatment. This suppo EPI-7386 benefiting tients that are less ad vanced, molecularl



Using a composite antitumor activity model including the elements described above, a dendrogram analysis shows that patients derivin clinical benefit from EPI-7386 administration tend to have a diseas prevalently driven by AR-axis alterations, lacking other alteration associated with multi-drug resistant disease.

Conclusions and Next Steps

• EPI-7386 monotherapy was safe and well tolerated up to a daily dose of 1200 mg (600 mg BID), achieved target clinical exposures and showed preliminary signals of antitumor activity in a clinically-defined patient subset which is primarily driven by AR molecular alterations

• The Phase 1b Dose Expansion is ongoing and testing 2 doses/schedules (600 mg BID and 600 mg QD) of single agent EPI-7386 in a less heavily pretreated mCRPC patient population (i.e., chemotherapy naive, post-second-generation antiandrogens)